Market capitalization | $71.68m |
Enterprise Value | $42.63m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.09 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-25.24m |
Free Cash Flow (TTM) Free Cash Flow | $-20.81m |
Cash position | $29.05m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Landos Biopharma Inc:
1 Analyst has issued a forecast Landos Biopharma Inc:
Mar '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -25 -25 |
21%
21%
|
EBIT (Operating Income) EBIT | -25 -25 |
21%
21%
|
Net Profit | -25 -25 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Landos Biopharma, Inc. engages in the development and commercialization of novel therapeutics for autoimmune diseases. The firm offers BT-11, a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. It also offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.
Head office | United States |
CEO | Gregory Oakes |
Employees | 19 |
Founded | 2017 |
Website | www.landosbiopharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.